Clinical Trial: Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07387471) titled 'Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)' on Jan. 28.

Brief Summary: Lymphoplasmacytic Lymphoma (LPL) is a rare type of low-grade B-cell lymphoma. The purpose of this study is to assess the change in disease activity of adult participants with relapsed or refractory Waldenstrom macroglobulinemia(WM)/LPL receiving venetoclax.

Venetoclax is being investigated in the treatment of WM/LPL. Participants will receive oral venetoclax at doses ramping up to the target dose, as part of trea...